<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04188028</url>
  </required_header>
  <id_info>
    <org_study_id>2018-01637</org_study_id>
    <nct_id>NCT04188028</nct_id>
  </id_info>
  <brief_title>Endobiotics for Phenotyping of Human Cytochrome P450 Enzymes</brief_title>
  <acronym>ENDOCYP2D6</acronym>
  <official_title>Endobiotics for Phenotyping of Human Cytochrome P450 Enzymes: Use of Metabolomics for the Identification of New CYP2D6 Endogenous Biomarkers in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Desmeules</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CYP2D6 metabolizes ~25% of all marketed drugs. There is an important variability in the
      activity of this enzyme among individuals. The cause of this variability might be
      environmental, genetic, ethnical or even related to a disease. The administration of a CYP2D6
      probe drug (e.g. dextromethorphan) is a good way to characterize CYP2D6 phenotype.
      Nonetheless, it is relatively invasive and the vulnerable population (e.g. pregnant women)
      cannot be phenotyped in this manner. Therefore, finding an endogenous substance which is
      metabolized by CYP2D6 could replace usual phenotyping procedure using a probe drug. This
      study evaluates the impact of a CYP2D6 inhibitor and of genetic polymorphism on the
      metabolome of healthy volunteers in order to identify new CYP2D6 biomarkers. To this end,
      untargeted metabolomics analysis using LC-HRMS will be performed on plasma and urine samples
      This single-centre open-label clinical trial will include 40 healthy subjects (men and women)
      between 18 and 65 years. Eligible participants will be assigned to a study group according to
      their CYP2D6 genotypes: poor metabolizers (PMs) and extensive/ultrarapid metabolizers
      (EMs-UMs). Two sessions will take place for each subjects.

      Session 1: CYP2D6 phenotyping (dextromethorphan 5 mg, single dose) Session 2: idem session 1
      with prior uptake of a CYP2D6 inhibitor (paroxetine 10 or 20 mg, one dose a day for 7 days).

      In both sessions, urine will be collected up to 24 hours and capillary/venous blood will be
      sampled before phenotyping for metabolomics analyses. Urine will also be collected for 4
      hours after dextromethorphan intake in order to phenotype the CYP2D6 enzyme.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identify endogenous markers of CYP2D6 activity in urine and plasma using untargeted metabolomics</measure>
    <time_frame>7 days</time_frame>
    <description>Metabolomic strategie (LC-Q-Exactive HRMS) will be used to identify and characterize endogenous compounds that correlate with the urinary metabolic ratio dextromethorphan/dextrorphan before and after administration of paroxetine, a strong CYP2D6 inhibitor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in DEM/DOR urinary ratio before and after administration of paroxetine</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of significant ions with DEM/DOR urinary ratio or CYP2D6 activity score</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CYP2D6 gene score 0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CYP2D6 gene score 0: carrier of two non-functional alleles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYP2D6 gene score ≥1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CYP2D6 gene score ≥1: carrier of one fully-functional and one non-functional allele of CYP2D6 , one fully-functional and one reduced-function of CYP2D6, two fully-functional alleles of CYP2D6 or more than two functional alleles alleles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan 5 MG</intervention_name>
    <description>dextromethorphan 5 mg po</description>
    <arm_group_label>CYP2D6 gene score 0</arm_group_label>
    <arm_group_label>CYP2D6 gene score ≥1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine 10Mg Tablet</intervention_name>
    <description>Paroxetine 10 mg po</description>
    <arm_group_label>CYP2D6 gene score 0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine 20Mg Tablet</intervention_name>
    <description>Paroxetine 20 mg po</description>
    <arm_group_label>CYP2D6 gene score ≥1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women

          -  Age 18-65 years

          -  Body Mass Index (BMI) 18-27

          -  Understanding of French language and able to give a written inform consent

          -  CYP2D6 genotype : activity score = 0 (PMs) or activity score ≥ 1 (EMs-UMs)

          -  Reliable contraception during the whole study, including a barrier method

        Exclusion Criteria:

          -  Participation in any other interventional clinical study within 3 months prior to
             inclusion

          -  Pregnant or breastfeeding woman

          -  Any pathologies, use of drugs or food that may affect CYP activity (based on the 'drug
             interactions and cytochromes P450' table published by the Service of Clinical
             Pharmacology and Toxicology, HUG54 and on the investigator's knowledge)

          -  Regular smokers of ≥ 10 cigarettes/day

          -  Alcohol intake 2 days prior to session 1 and during paroxetine intake

          -  Medical history of chronic alcoholism or abuse of psychoactive drugs

          -  Regular use of psychotropic substances

          -  Sensitivity to any of the drugs used

          -  Alteration of hepatic tests (ASAT, ALAT, BILI, GGT) more than 3x normal

          -  Psychiatric disorders

          -  Beck Score ≥10 (question related to suicide &gt;0)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gaelle Magliocco</last_name>
    <phone>+41 (0)22 379 4995</phone>
    <email>gaelle.magliocco@hcuge.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>HUG</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaelle Magliocco</last_name>
      <phone>+41 (0)22 379 4995</phone>
      <email>gaelle.magliocco@hcuge.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2019</study_first_posted>
  <last_update_submitted>December 4, 2019</last_update_submitted>
  <last_update_submitted_qc>December 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Jules Desmeules</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

